

# CITATION REPORT

List of articles citing

## Withdrawal of Posicor from market

DOI: 10.1161/01.cir.98.9.831  
Circulation, 1998, 98, 831-2.

**Source:** <https://exaly.com/paper-pdf/29525102/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
80	Adrenoceptor antagonists and antianginal drugs. <i>Side Effects of Drugs Annual</i> , <b>2000</b> , 23, 206-213	0.2	
79	The effect of mibefradil on ischemic episodes with and without increase in heart rate. <i>Cardiovascular Drugs and Therapy</i> , <b>2000</b> , 14, 503-9	3.9	3
78	Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. <i>Clinical Pharmacology and Therapeutics</i> , <b>2000</b> , 68, 345-55	6.1	214
77	bijwerkingen, meldenBijwerkingen van nieuwe geneesmiddelen weinig gemeld. <i>Medisch-farmaceutische Mededelingen</i> , <b>2000</b> , 38, 60-60		
76	Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. <i>Pediatric Nephrology</i> , <b>2000</b> , 15, 302-16	3.2	87
75	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. <i>Xenobiotica</i> , <b>2000</b> , 30, 27-46	2	36
74	Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. <i>Circulation</i> , <b>2000</b> , 101, 1749-53	16.7	45
73	Effect of mibefradil on heart rate variability in patients with chronic heart failure. <i>International Journal of Cardiology</i> , <b>2000</b> , 73, 55-60	3.2	4
72	Drug block of I(kr): model systems and relevance to human arrhythmias. <i>Journal of Cardiovascular Pharmacology</i> , <b>2001</b> , 38, 737-44	3.1	160
71	Antihypertensive pharmacogenetics: getting the right drug into the right patient. <i>Journal of Hypertension</i> , <b>2001</b> , 19, 1-11	1.9	56
70	Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. <i>European Heart Journal Supplements</i> , <b>2001</b> , 3, K70-K80	1.5	148
69	Mibefradil ? a drug which may enhance the propensity for the development of abnormal QT prolongation. <i>European Heart Journal Supplements</i> , <b>2001</b> , 3, K89-K92	1.5	12
68	Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial. <i>American Heart Journal</i> , <b>2002</b> , 144, 60-7	4.9	16
67	Selective L-type, T-type, and nonspecific calcium-channel blockers for stable angina pectoris. <i>American Heart Journal</i> , <b>2002</b> , 144, 8-10	4.9	23
66	Statin-associated myopathy. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 289, 1681-90	27.4	1002
65	High-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes. <i>Xenobiotica</i> , <b>2003</b> , 33, 823-39	2	17
64	[Drug interactions in the elderly]. <i>Deutsche Medizinische Wochenschrift</i> , <b>2004</b> , 129, 895-900	0	6

63	3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA. <i>Bioorganic and Medicinal Chemistry</i> , <b>2004</b> , 12, 1613-21	3.4	15
62	First pharmacophoric hypothesis for T-type calcium channel blockers. <i>Bioorganic and Medicinal Chemistry</i> , <b>2004</b> , 12, 1605-11	3.4	32
61	Variability in Cytochrome P450-Mediated Metabolism of Cardiovascular Drugs: Clinical Implications and Practical Attempts to Avoid Potential Problems. <i>Cardiology</i> , <b>2004</b> , 4, 55-79		6
60	[Psychopharmacotherapy in somatic diseases -- treatment principles in daily medical routine]. <i>Wiener Medizinische Wochenschrift</i> , <b>2005</b> , 155, 303-14	2.9	13
59	Class effects and labeling of antihypertensive drugs. <i>Journal of Clinical Hypertension</i> , <b>2006</b> , 8, 215-20	2.3	3
58	Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms. <i>Pharmacology</i> , <b>2006</b> , 78, 11-20	2.3	35
57	Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model. <i>Current Drug Metabolism</i> , <b>2006</b> , 7, 135-46	3.5	2
56	Design, synthesis, and biological evaluation of 1,3-dioxoisindoline-5-carboxamide derivatives as T-type calcium channel blockers. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2007</b> , 17, 476-81	2.9	23
55	Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2007</b> , 852, 128-37	3.2	26
54	Diagnostik und Psychopharmakotherapie depressiver Erkrankungen bei Herz-Kreislauf-Patienten vor konsiliarpsychiatrischem Hintergrund. <i>Psychosomatik Und Konsiliarpsychiatrie</i> , <b>2007</b> , 1, 139-143		2
53	Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector?. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 65, 364-76	3.8	13
52	The mibefradil derivative NNC55-0396, a specific T-type calcium channel antagonist, exhibits less CYP3A4 inhibition than mibefradil. <i>Drug Metabolism and Disposition</i> , <b>2008</b> , 36, 1291-9	4	25
51	Cytochrome P450: Structure, Function, and Application in Drug Discovery and Development. 55-107		
50	Predicting the clinical relevance of drug interactions from pre-approval studies. <i>Drug Safety</i> , <b>2009</b> , 32, 1017-39	5.1	14
49	KST5468, a new T-type calcium channel antagonist, has an antinociceptive effect on inflammatory and neuropathic pain models. <i>Pharmacology Biochemistry and Behavior</i> , <b>2010</b> , 97, 198-204	3.9	14
48	Synthesis and biological evaluation of oxazole derivatives as T-type calcium channel blockers. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2010</b> , 20, 4219-22	2.9	16
47	Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2010</b> , 20, 6375-8	2.9	11
46	Cardiovascular drugs inducing QT prolongation: facts and evidence. <i>Current Drug Safety</i> , <b>2010</b> , 5, 65-72	1.4	18

45	Ion Channels and Their Inhibitors. <b>2011</b> ,		2
44	Synthesis and pharmacological evaluation of 1-isopropyl-1,2,3,4-tetrahydroisoquinoline derivatives as novel antihypertensive agents. <i>Chemical and Pharmaceutical Bulletin</i> , <b>2011</b> , 59, 1029-37	1.9	6
43	Synthesis and pharmacological evaluation of 1-alkyl-N-[(1R)-1-(4-fluorophenyl)-2-methylpropyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents. <i>Chemical and Pharmaceutical Bulletin</i> , <b>2011</b> , 59, 1376-85	1.9	5
42	Utility of frozen cell lines in medium throughput electrophysiology screening of hERG and NaV1.5 blockade. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>2011</b> , 64, 269-76	1.7	16
41	Synthesis and pharmacological evaluation of 1-alkyl-N-[2-ethyl-2-(4-fluorophenyl)butyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents. <i>Bioorganic and Medicinal Chemistry</i> , <b>2011</b> , 19, 5628-38	3.4	8
40	Reliable high-throughput method for inhibition assay of 8 cytochrome P450 isoforms using cocktail of probe substrates and stable isotope-labeled internal standards. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2012</b> , 27, 520-9	2.2	45
39	Cav3 T-type calcium channels. <i>Environmental Sciences Europe</i> , <b>2012</b> , 1, 467-491	5	19
38	Pharmacointeraction network models predict unknown drug-drug interactions. <i>PLoS ONE</i> , <b>2013</b> , 8, e61468	3.7	43
37	Pharmacology of Voltage-Gated Calcium Channels in Clinic. <b>2014</b> , 297-314		
36	Targeting ion channels for cancer therapy by repurposing the approved drugs. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , <b>2015</b> , 1848, 2747-55	3.8	46
35	Mibefradil. <b>2016</b> , 1007-1009		
34	The Evolution of Clinical Development: From Technical Success to Clinical Value Creation. <b>2016</b> , 202-223		
33	System Prediction of Drug-Drug Interactions Through the Integration of Drug Phenotypic, Therapeutic, Structural, and Genomic Similarities. <i>Lecture Notes in Computer Science</i> , <b>2016</b> , 377-385	0.9	
32	Mibefradil represents a new class of benzimidazole TRPM7 channel agonists. <i>Pflugers Archiv European Journal of Physiology</i> , <b>2016</b> , 468, 623-34	4.6	21
31	Polypharmazie in der Behandlung psychischer Erkrankungen. <b>2016</b> ,		2
30	Development and validation of an in vitro, seven-in-one human cytochrome P450 assay for evaluation of both direct and time-dependent inhibition. <i>Journal of Pharmacological and Toxicological Methods</i> , <b>2016</b> , 77, 66-75	1.7	13
29	Catalytic asymmetric synthesis of 2,3,3,3-tetrafluoro-2-methyl-1-arylpropan-1-amines as useful building blocks for SAR-studies. <i>Journal of Fluorine Chemistry</i> , <b>2017</b> , 194, 1-7	2.1	16
28	CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information. <i>Regulatory Toxicology and Pharmacology</i> , <b>2017</b> , 88, 238-251	3.4	24

27	Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2018</b> , 33, 1460-1471	5.6	1
26	Clinical trials on drug-drug interactions registered in ClinicalTrials.gov reported incongruent safety data in published articles: an observational study. <i>Journal of Clinical Epidemiology</i> , <b>2018</b> , 104, 35-45	5.7	3
25	Calcium Channel Blockers. <b>2018</b> , 242-253		1
24	Mibefradil, a T-type Ca channel blocker also blocks Orai channels by action at the extracellular surface. <i>British Journal of Pharmacology</i> , <b>2019</b> , 176, 3845-3856	8.6	17
23	The Role of Rain-on-Snow in Flooding Over the Conterminous United States. <i>Water Resources Research</i> , <b>2019</b> , 55, 8492-8513	5.4	32
22	Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2019</b> , 29, 1168-1172	2.9	
21	Computational prediction of cytochrome P450 inhibition and induction. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2020</b> , 35, 30-44	2.2	18
20	Drug-drug interaction trials incompletely described drug interventions in ClinicalTrials.gov and published articles: an observational study. <i>Journal of Clinical Epidemiology</i> , <b>2020</b> , 117, 126-137	5.7	2
19	Antihypertensives and melanoma: An updated review. <i>Pigment Cell and Melanoma Research</i> , <b>2020</b> , 33, 806-813	4.5	2
18	Novel Therapeutic Approaches of Ion Channels and Transporters in Cancer. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , <b>2020</b> , 1	2.9	2
17	The ADME Encyclopedia. <b>2021</b> , 1-9		
16	Pharmacokinetic characterization of drugs and new product development. <b>2021</b> , 195-277		0
15	Chemical Aspects of Human and Environmental Overload with Fluorine. <i>Chemical Reviews</i> , <b>2021</b> , 121, 4678-4742	68.1	49
14	Animal venom peptides cause antinociceptive effects by voltage-gated calcium channels activity blockage. <i>Current Neuropharmacology</i> , <b>2021</b> ,	7.6	1
13	Polypharmazie in der Konsiliar- und Liaisonpsychiatrie. <b>2006</b> , 173-195		1
12	Polypharmazie in der Konsiliar-und Liaisonpsychiatrie. <b>2009</b> , 189-214		1
11	Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187072	3.7	13
10	A profile of adverse effects of antihypertensive medicines in a tertiary care clinic in Nigeria. <i>Annals of African Medicine</i> , <b>2017</b> , 16, 114-119	1.7	14

- 9 Myocardial Infarction Agents. **2003**, 155-192
- 8 Mibefradil. **2006**, 2335-2336
- 7 Depressive und Angststörungen bei somatischen Krankheiten. **2008**, 1501-1566 1
- 6 Drugs Used to Treat Hypertension, Heart Failure, and Angina Pectoris. **2009**, 1-196
- 5 Calcium Ion Channels and Their Blockers. **2011**, 265-288
- 4 Informationssysteme als Hilfsmittel eines Qualitätsmanagements. Teil 2: Praktische Umsetzung. *Langenbecks Archiv Für Chirurgie Supplement*, **1999**, 1538-1548
- 3 Konsiliar- und Liaisonpsychiatrie. **2016**, 187-208
- 2 Antipsychotic agents and QT changes. *Journal of Psychiatry and Neuroscience*, **2000**, 25, 154-60 4.5 68
- 1 Drug-Drug and Food-Drug Interactions. **2022**, 448-456 0